I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 0.9397 USD -2.01% Market Closed
Market Cap: 76m USD
Have any thoughts about
I-Mab?
Write Note

Relative Value

The Relative Value of one IMAB stock under the Base Case scenario is 0.7454 USD. Compared to the current market price of 0.9397 USD, I-Mab is Overvalued by 21%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMAB Relative Value
Base Case
0.7454 USD
Overvaluation 21%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
53
vs Industry
27
Median 3Y
23.4
Median 5Y
24
Industry
7.7
vs History
vs Industry
11
Median 3Y
-0.8
Median 5Y
-0.9
Industry
22.7
Forward
-1.2
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-5.8
Industry
21.6
vs History
vs Industry
Median 3Y
-2
Median 5Y
-5.4
Industry
25.2
vs History
93
vs Industry
72
Median 3Y
0.6
Median 5Y
1.2
Industry
2.5
vs History
vs Industry
47
Median 3Y
4.7
Median 5Y
7.6
Industry
7.7
vs History
vs Industry
50
Median 3Y
-0
Median 5Y
-46.8
Industry
9
vs History
11
vs Industry
15
Median 3Y
0.9
Median 5Y
0.6
Industry
4.2
Forward
1.2
vs History
11
vs Industry
13
Median 3Y
0.9
Median 5Y
0.6
Industry
4.1
Forward
15.9
vs History
15
vs Industry
16
Median 3Y
1.5
Median 5Y
-0.7
Industry
5.7
vs History
15
vs Industry
12
Median 3Y
1.5
Median 5Y
-0.7
Industry
3.6
vs History
8
vs Industry
6
Median 3Y
33.4
Median 5Y
23.4
Industry
4.6

Multiples Across Competitors

IMAB Competitors Multiples
I-Mab Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
I-Mab
NASDAQ:IMAB
76m USD 19.9 -0.4 1.4 1.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
CN
I-Mab
NASDAQ:IMAB
Average P/E: 208.3
Negative Multiple: -0.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
I-Mab
NASDAQ:IMAB
Average EV/EBITDA: 14.9
1.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
CN
I-Mab
NASDAQ:IMAB
Average EV/EBIT: 19.5
1.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top